Dogwood Therapeutics Inc DWTX 深 沪
已收盘 04-02 16:00:00 美东时间
2.11
-0.020
-0.94%
华盛通- 最 高2.20
- 今 开2.135
- 成交量 1.89万股
- 最 低 2.0604
- 昨 收 2.13
- 总市值 7047.73万
- 52周最高 9.50
- 市盈率 静 --
- 换手率 0.06%
- 52周最低 1.77
- 委 比 5.10%
- 总股本 3340.16万
- 历史最高 417.75
- 量 比 0.25
- 振 幅 6.55%
- 历史最低 1.77
- 每 手 1
- 风险率 1.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Dogwood Therapeutics Q4 net loss narrows on lower expenses
Dogwood Therapeutics Q4 net loss narrows on lower expenses Overview US biotechnology developer's Q4 net loss narrowed yr/yr due to lower administrative expenses Full year net loss widened, driven by increased R&D expenses for clinical trials and licensing Company completed $26.9 mln financing in Jan
03-18 20:38
Dogwood Therapeutics Q4 EPS $(0.26) Beats $(1.17) Estimate
Dogwood Therapeutics (NASDAQ:DWTX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(1.17) by 77.83 percent. This is a 95.87 percent increase over losses of $(6.29) per share
03-18 20:34
Dogwood Therapeutics FY2025 net loss attributable to common stockholders widens to USD 35.51 million as R&D spending rises more than sixfold to USD 21.87 million
Dogwood Therapeutics FY2025 net loss attributable to common stockholders widens to USD 35.51 million as R&D spending rises more than sixfold to USD 21.87 million Dogwood Therapeutics published a press release reporting Q4 and full-year 2025 financial results. Q4 net loss attributable to common stock
03-18 20:32
美股大行评级 | 苹果、SanDisk、西部数据、卡特彼勒、德克斯户外、霍尼韦尔、西南航空、万事达等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Praxis Precision Medicine"买入"评级，目标价从340美元升至1245美元；HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从10美元升至12美元
02-02 14:15
HC Wainwright & Co. Reiterates Buy on Dogwood Therapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Sean Lee reiterates Dogwood Therapeutics (NASDAQ:DWTX) with a Buy and maintains $12 price target.
01-30 19:26
Dogwood Therapeutics Highlights Pipeline Expansion And Clinical Progress Toward Non-Opioid Cancer Pain And Neuropathy Treatments; Key Halneuron And SP16 Milestones Targeted For 2026
Dogwood Therapeutics, Inc. (NASDAQ:DWTX) ("DWTX" or "Company"), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, issues a corporate update in the following Letter to
01-20 21:37
What's Driving the Market Sentiment Around Dogwood Therapeutics Inc?
Dogwood Therapeutics Inc's (NYSE:DWTX) short interest as a percent of float has...
2025-12-25 00:00
Dogwood Therapeutics Reports Interim Results For Halneuron In Chemotherapy-Induced Neuropathic Pain Study; Expects Top-Line Results Availability In Q3 2026
- Halneuron® treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 -- The overall study dropout rate of ~4.4% is far below rates typically
2025-12-22 23:17
Dogwood Therapeutics Files For New Intellectual Property Protection For Synthetic Halneuron
Dogwood Therapeutics, Inc. (Nasdaq:DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced it has filed for new intellectual property
2025-12-02 21:04
Dogwood Therapeutics Launches $8.56M At-The-Market Stock Offering Under New Equity Distribution Agreement
On November 28, 2025, Dogwood Therapeutics, Inc., a Delaware corporation (the "Company"), entered into an Equity Distribution Agreement (the "Agreement") with Northland Securities, Inc. (trade
2025-11-29 03:52
